France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund
Executive Summary
The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.
You may also be interested in...
France Relaxes Stance On Biosimilar Switching
The French regulatory agency ANSM has relaxed its stance on biosimilar interchangeability to state that while in principle patients should preferably not be switched between a reference drug and a biosimilar during their course of treatment, this can be done provided the patient agrees and their treatment is closely monitored1.
French Industry Rages Over €1.7bn Drug Savings Plan
Measure includes €550bn in drug price cuts.
Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives
Eurordis has welcomed some parts of the leaked proposals for overhauling the EU medicines legislation, but it has a number of concerns, including the future role of patient representatives if the European Medicines Agency’s committee structure is slimmed down as planned.